Context Therapeutics is focused on advancing the development of T cell engaging (TCE) bispecific antibody therapies specifically designed to target solid tumors. Their innovative approach involves creating bispecific antibodies that can simultaneously bind to tumor-associated antigens and T cells, thereby enhancing the immune response against cancer cells. The company is building a robust pipeline of clinical-stage therapeutics, which includes several promising product candidates aimed at different tumor targets.

Among their key product candidates are CTIM-76, which targets Claudin 6 (CLDN6) in conjunction with CD3; CT-95, which targets Mesothelin (MSLN) alongside CD3; and CT-202, which focuses on Nectin-4 in combination with CD3. These bispecific antibodies are designed to harness the power of the immune system to effectively combat solid tumors, representing a significant advancement in cancer immunotherapy. Context Therapeutics is committed to pushing the boundaries of T cell engagement to improve treatment outcomes for patients with challenging solid tumors.

United States

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.

Cancer

Context Therapeutics

Cervical cancer

Ovarian cancer

Solid tumor/s

Testicular cancer

CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.

CTIM-76

CT-95 is a fully humanized bispecific TCE that employs an IgG-scFv architecture with an effector-silenced IgG1 backbone and has a relatively low affinity but high avidity for membrane-bound MSLN, minimizing the impact of the shed sink. CT-95 is being developed as a therapy for advanced cancers associated with MSLN expression. MSLN is a membrane protein overexpressed by many cancers with limited expression in normal tissues. One challenge in developing MSLN-targeted therapies has been the presence of a shed MSLN sink found in both blood and the tumor microenvironment.

CT-95

Endometrial cancer

ONA-XR is an investigational medicine that prevents progesterone signaling by blocking the interaction between progesterone and its binding partner, progesterone receptor. Onapristone is the only known full PR antagonist.

Context Therapeutics

Company Details